Table 4

Volatile fatty acid (VFA) concentrations (μmol/g faeces) determined by tertbutyldimethylsilyl derivatisation and GC analysis for forty volunteers over the trial period during which they were consuming control, placebo or experimental bread products enriched with AXOS. (Mean values and standard deviations)
baseline control bread pre- placebo treatment placebo treatment post- placebo washout pre- AXOS treatment AXOS treatment post- AXOS washout
Acetate 45.6 ±27.9 47.3 ±21.8 51.1 ±18.8 54.2 ±26.4 48.0 ±22.5 46.7 ±22.3 55.1 ±34.5 52.1 ±19.6
Propionate 17.8 ±13.7 16.5 ±11.1 18.2 ±10.1 19.5 ±11.2 17.1 ±10.9 16.1 ±10.9c 17.5 ±10.4 18.8 ±8.6b
Butyrate 11.5 ±7.9 13.6 ±9.4 14.9 ±10.1 14.6 ±7.2a 15.0 ±10.1 12.8 ±8.8 16.3 ±12.3ab 14.5 ±7.9
Total acetate, propionate and butyrate 74.9 ±44.7 77.4 ±37.0 84.2 ±33.3 87.8 ±6.2 80.2 ±38.3 75.6 ±36.9 88.9 ±52.4 85.4 ±31.6
Valerate 1.2 ±1.4 2.3 ±2.3a 2.4 ±2.3a 2.2 ±1.8a 2.0 ±2.3 2.4 ±1.5a 2.3 ±2.2a 1.7 ±2.0
Iso-valerate 1.3 ±0.6 1.3 ±1.0 1.5 ±1.3 1.3 ±1.1 1.7 ±1.1 1.4 ±0.7 1.1 ±1.0 1.7 ±2.0
Caproate 0.8 ±0.8 0.7 ±0.9 0.9 ±1.3 1.0 ±1.4 0.8 ±0.8 0.8 ±0.8 0.7 ±0.8 1.1 ±1.4
Iso-butyrate 1.7 ±0.7 1.6 ±1.2 1.9 ±1.5 1.7 ±1.3 1.8 ±1.2 1.6 ±0.9 1.3 ±1.1 1.8 ±1.3
Total valerate, iso-valerate, caproate and iso-butyrate 4.9 ±2.5 5.8 ±4.5 6.7 ±5.0 6.2 ±4.9a 6.2 ±3.7 6.1 ±2.8 5.4 ±4.2 6.3 ±4.5

P-values of VFA changes. Wilcoxons signed rank test was used to determine statistical differences between levels of VFA, as this data did not follow a normal distribution.

a - different to baseline; b- different to pre-treatment; c- different to washout, (p < 0.05).

Walton et al.

Walton et al. Nutrition Journal 2012 11:36   doi:10.1186/1475-2891-11-36

Open Data